Anticipating Scale
Infrastructure, Strategy, and the future of ATMPs in Europe
Scientific advances in cell and gene therapies are reshaping clinical possibilities, building momentum behind therapeutic innovation as new approaches to improving human health are entering clinical trials or commercialization seemingly every day. Yet the infrastructure required to support these therapies remains uneven and under strain. The challenge is not simply logistical. It’s structural, systemic, and deeply tied to how the industry prepares for scale.
This whitepaper explores the current landscape and future of advanced therapy medicinal products (ATMPs) in Europe, focusing on the infrastructure and strategic considerations required to support the anticipated scale of cell and gene therapies. Explore some the opportunities and challenges facing ATMPs, including:
- Regulatory and Market Access Challenges
- Operational Complexities Straining the Supply Chain
- Building Resilient and Scalable Supply Chains
- Outsourcing to Minimize Capital Expenditure
- Adapting to Geopolitical and Market Dynamics
Download the whitepaper and learn how Cryoport Systems is designing the future of ATMP delivery.